Malcolm MacEachern Symposium 2022

International PRogram professor of management, Mit, Sloan school of Management

Pierre Azoulay is the International Programs Professor of Management at the MIT Sloan School of Management, and a Research Associate at the National Bureau of Economic Research.
His current research focuses on empirical studies of the supply of biomedical innovators, particularly at the interface of academia and the biopharmaceutical industry. He also is interested in the topic of academic entrepreneurship, having recently concluded a major study of the antecedents and consequences of academic patenting. In the past, he has investigated the impact of superstar researchers on the research productivity of their colleagues, and the outsourcing strategies of pharmaceutical firms, in particular the role played by contract research organizations in the clinical trials process.
At MIT Sloan, he teaches courses on competitive strategy and innovation strategy to the EMBA students and Sloan Fellows, as well as a PhD class on the economics of ideas, innovation, and entrepreneurship.
He holds a Diplôme d’Études Supérieures de Gestion from the Institut National des Télécommunications, an MA from Michigan State University, and a PhD in management from MIT.

Former FDA Commissioner

Scott Gottlieb, MD is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration from 2017 to 2019. Dr. Gottlieb’s work focuses on advancing public health through developing and implementing innovative approaches to improving medical outcomes, reshaping healthcare delivery, and expanding consumer choice and safety. He is currently a senior fellow at the American Enterprise Institute and a member of the board of directors of Pfizer, Inc, Illumina Inc, and Tempus Labs. Dr. Gottlieb is a partner at the venture capital firm New Enterprise Associates where he is a member of the firm’s healthcare services and biopharma investment teams. For NEA, he serves on the boards of National Resilience and Aetion.

Under his leadership, the FDA advanced new frameworks for the modern and safe and effective oversight of gene therapies, cell based regenerative medicines, targeted drugs, and digital health devices. The agency advanced new models for the regulation of artificial intelligence devices, veterinary medicines, and orphan drugs; and implemented new reforms to standardize drug reviews and make important improvements in post market data collection and the use of realworld evidence. The agency’s historic and prolific advances in new policy distinguished his tenure as the FDA’s commissioner, in addition to a record-setting number of approvals of novel drugs, medical devices, and generic medicines in 2018 and again in 2019.

Dr. Gottlieb promoted policies to reduce death and disease from tobacco, improve food innovation and safety, expand the agency’s oversight of areas of emerging risk such as dietary supplements and cell-based medicine, and aggressively confront addiction crises. The FDA advanced new legislative frameworks to address the opioid crisis, grow its field operations, and modernize the regulation of diagnostic tests and over-the-counter drugs, among other initiatives. Dr. Gottlieb forged collaborative relations with Congress that saw FDA increase its total budget by about $1 billion over two years. During his tenure, he testified before Congress 20 times.

Previously, Dr. Gottlieb served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and before that, as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services, where he helped implement the Medicare drug benefit, and advance policies to improve healthcare quality and promote the effective use of new medical technologies.

Dr. Gottlieb is author of the New York Times bestselling book “Uncontrolled Spread” and is widely published in leading medical journals and periodicals, including The Wall Street Journal, The New York Times, and The Washington Post. He holds an editorial position on the Journal of the American Medical Association. Fortune Magazine recognized him as one of the “World’s 50 Greatest Leaders” in 2018 and again in 2019. Modern Healthcare has named Dr. Gottlieb as one of the “Most Influential Physician Executive and Leaders” in its annual survey of 50 physician executives, and Time magazine named Dr. Gottlieb as one of its “50 People Transforming Healthcare in 2018.” He is a contributor to CNBC and CBS News Face the Nation.

Dr. Gottlieb was a practicing hospitalist and a Clinical Assistant Professor at the New York University School of Medicine. He is an elected member of the National Academy of Medicine.

chief clinical officer, cigna international


Dr. Steve Miller, is a nationally recognized advocate for greater access, affordability and excellence in healthcare. He is a trusted expert and advisor for Cigna’s efforts across clinical policy, quality and performance programs. He stepped into this role in 2022 after serving as the company’s Chief Clinical Officer for nearly five years. 

He formerly served as Express Scripts’ Senior Vice President and Chief Medical Officer, responsible for supporting government relations, leading the Pharmacy & Therapeutics committee, managing the Medical Affairs team, leading Government Affairs and interfacing with client groups. During his 12 years in that position, Dr. Miller focused on improving health outcomes and value through e-prescribing initiatives, specialty solutions and overall product development. 

Dr. Miller’s expertise represents years as a medical researcher, clinician and administrator, and spans numerous healthcare subjects. He previously was the vice president and chief medical officer at Barnes-Jewish Hospital, Washington University School of Medicine in St. Louis. 

Dr. Miller received his medical degree from the University of Missouri-Kansas City. He trained in the Pathology and Research fellowship at the University of Alabama at Birmingham. He was the William J. and Dorothy Fish Kerr Fellow in Cardiology at the University of California, San Francisco. Dr. Miller also did Internal Medicine training at the University of Colorado and Nephrology and Transplantation at Washington University in St. Louis. He earned his MBA at the Olin School of Business at Washington University.

Managing Director, Bain CApital Life Sciences

Dr. Sun joined Bain Capital Life Sciences in 2016. He is a Managing Director. Prior to joining Bain Capital, from 2013 to 2016, he was a Director of Corporate Development and Strategy at Biogen. Prior to Biogen, Dr. Sun served as a Vice President at BlackRock, as a member of the Fundamental Equity division of BlackRock's Alpha Strategies Group and senior analyst for BlackRock's Fundamental Large Cap Growth equity team, covering the health care sector. Prior to that, he was a senior healthcare analyst at Citadel and Alyeska Investment Group in Chicago and worked as a pharmaceuticals equity research analyst on Wall Street, spending time at Lehman Brothers and Morgan Stanley. Dr. Sun began his career as a senior scientist at Ironwood Pharmaceutical where he was involved in the discovery and development of the drug Linzess for irritable bowel syndrome.

Dr. Sun received a PhD degree in Chemistry and Chemical Biology from Harvard University and was an NIH post-doctoral fellow in Biological Chemistry & Molecular Pharmacology at Harvard Medical School.  He also received an MBA from New York University Stern School of Business, where he was a Mildred Elperin Scholar.  He graduated summa cum laude from Berea College with a BA in chemistry.